Laurion Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Laurion Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-15,900	Closed	-$11.3M	–	366
2024 Q4	$11.3M	Buy	+15,900	New	+$13.3M	0.21%	88
2019 Q4	–	Sell	-74,400	Closed	-$20.6M	–	1172
2019 Q3	$20.6M	Buy	74,400 +22,900	+44%	+$6.78M	0.15%	146
2019 Q2	$16.1M	Buy	51,500 +36,600	+246%	+$12.2M	0.16%	140
2019 Q1	$6.12M	Sell	14,900 -9,900	-40%	-$4.08M	0.08%	191
2018 Q4	$9.26M	Sell	24,800 -80,400	-76%	-$29.4M	0.16%	161
2018 Q3	$42.5M	Buy	105,200 +81,400	+342%	+$31M	0.41%	32
2018 Q2	$8.21M	Hold	23,800	–	–	0.07%	260
2018 Q1	$8.2M	Hold	23,800	–	–	0.07%	264
2017 Q4	$8.95M	Hold	23,800	–	–	0.05%	378
2017 Q3	$10.6M	Hold	23,800	–	–	0.05%	311
2017 Q2	$11.7M	Buy	23,800 +12,000	+102%	+$5.25M	0.06%	284
2017 Q1	$4.57M	Buy	+11,800	New	+$4.37M	0.03%	438

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Laurion Capital Management's REGN Position: Q1 2025 in Review

Laurion Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 524 shares — an estimated $373K sold.

Laurion Capital Management first reported a position in REGN in Q4 2016 and held it in 15 quarters. The position peaked at $6.98M in Q1 2022. 1,291 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

Laurion Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Laurion Capital Management sold 524 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $373K.
Laurion Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2016 and held it in 15 quarters.
Laurion Capital Management's Regeneron Pharmaceuticals position peaked at $6.98M in Q1 2022.
1,291 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Laurion Capital Management's 13F filing for Q1 2025, filed 15 May 2025.